• 1
    Albain KS,Rusch VW,Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995; 13: 18801892.
  • 2
    Kadri MA,Dussek JE. Survival and prognosis following resection of primary non small cell bronchogenic carcinoma. Eur J Cardiothorac Surg. 1991; 5: 132136.
  • 3
    Takeda S,Maeda H,Koma M, et al. Comparison of surgical results after pneumonectomy and sleeve lobectomy for non-small cell lung cancer: trends over time and 20-year institutional experience. Eur J Cardiothorac Surg. 2006; 29: 276280.
  • 4
    Albain KS,Rusch VR,Turrisi AT, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93–09). Proc Am Soc Clin Oncol. 2003; 22. Abstract 2497.
  • 5
    Sugarbaker DJ,Flores RM,Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999; 117: 5463; discussion 63–65.
  • 6
    Begg CB,Cramer LD,Hoskins WJ,Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998; 280: 17471751.
  • 7
    Watanabe H,Yamamoto S,Kunitoh H, et al. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci. 2003; 94: 10151020.
  • 8
    Maggi G. Results of radical treatment of stage IIIa non-small-cell carcinoma of the lung. Eur J Cardiothorac Surg. 1988; 2: 329335.
  • 9
    Sabanathan S,Richardson J,Mearns AJ,Goulden C. Results of surgical treatment of stage III lung cancer. Eur J Cardiothorac Surg. 1994; 8: 183187.
  • 10
    Wada H,Fukuse T,Hitomi S. Long-term survival of surgical cases of lung cancer. Lung Cancer. 1995; 13: 269274.
  • 11
    Alam N,Shepherd FA,Winton T, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer. 2005; 47: 385394.
  • 12
    Curran W,Scott C,Langer C, et al. Phase III comparison of sequential vs concurrent chemo radiation for pts. with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 94–10. Proc of Am Soc Clin Oncol (ASCO), New Orleans, LA. J Clin Oncol. 2000; 484a. Abstract 1891.
  • 13
    Zatloukal P,Petruzelka L,Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 2004; 46: 8798.
  • 14
    Fournel P,Robinet G,Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non- small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95–01 Study. J Clin Oncol. 2005; 23: 59105917.
  • 15
    Dillman RO,Seagren SL,Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990; 323: 940945.
  • 16
    Rusch VW,Giroux DJ,Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 2001; 121: 472483.
  • 17
    Martin J,Ginsberg RJ,Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg. 2001; 72: 11491154.
  • 18
    Ludwig C,Stoelben E,Olschewski M,Hasse J. Comparison of morbidity, 30-day mortality, and long-term survival after pneumonectomy and sleeve lobectomy for non-small cell lung carcinoma. Ann Thorac Surg. 2005; 79: 968973.
  • 19
    Sugarbaker DJ,Jaklitsch MT,Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004; 128: 138146.
  • 20
    Urschel JD,Urschel DM. The hospital volume-outcome relationship in general thoracic surgery. Is the surgeon the critical determinant? J Cardiovasc Surg (Torino). 2000; 41: 153155.
  • 21
    Goodney PP,Lucas FL,Stukel TA,Birkmeyer JD. Surgeon specialty and operative mortality with lung resection. Ann Surg. 2005; 241: 179184.
  • 22
    Bach PB,Cramer LD,Schrag D,Downey RJ,Gelfand SE,Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med. 2001; 345: 181188.
  • 23
    Ghosh S,Steyn RS,Marzouk JF,Collins FJ,Rajesh PB. The effectiveness of high dependency unit in the management of high risk thoracic surgical cases. Eur J Cardiothorac Surg. 2004; 25: 123126.
  • 24
    Harpole DH,Liptay MJ,DeCamp MMJr,Mentzer SJ,Swanson SJ,Sugarbaker DJ. Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg. 1996; 61: 977982.
  • 25
    Sugarbaker DJ,Grondin SC. Techniques of pneumonectomy. Pleural pneumonectomy. Chest Surg Clin N Am. 1999; 9: 379392,xi.
  • 26
    Sonett JR,Suntharalingam M,Edelman MJ, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg. 2004; 78: 12001205; discussion 1206.
  • 27
    Vaporciyan AA,Merriman KW,Ece F, et al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. Ann Thorac Surg. 2002; 73: 420425; discussion 25–26.
  • 28
    Choi NC,Carey RW,Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 1997; 15: 712722.
  • 29
    Bueno R,Richards WG,Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg. 2000; 70: 18261831.